Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
Coeptis Therapeutics Holdings Inc. reports corporate-status, capital-structure and biotechnology developments associated with the company that became Z Squared Inc. after a completed merger and name change. News tied to COEP includes shareholder voting matters, governance updates, operating and financial results, and material agreements.
The company’s biotechnology-related updates include clinical or regulatory disclosures and licensing activity involving majority-owned SNAP Biosciences, the SNAP-CAR NK cell therapy platform, and oncology applications using small-molecule adaptor technology. Later corporate updates center on capital structure, security-status changes and formal transaction disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Coeptis Therapeutics (NASDAQ: COEP) announced a proposed transaction to acquire assets from Deverra Therapeutics, focusing on NK cell therapies for relapsed/refractory acute myeloid leukemia (AML) and respiratory infections. The agreement grants Coeptis exclusive negotiation rights until August 31, 2023, for two IND applications and Phase 1 trials involving NK cell therapy. This acquisition aims to enhance Coeptis' R&D capabilities and diversify its portfolio by integrating a proven allogeneic platform that requires no HLA matching. With anticipated Phase 1 AML trial data expected in 2H 2023, the deal could significantly expand Coeptis' technological footprint. If completed, Deverra's CSO, Dr. Colleen Delaney, is expected to join Coeptis as Chief Scientific and Medical Officer.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has acquired exclusive rights to negotiate for the acquisition of VyGen-Bio, enhancing its oncology pipeline. The GEAR™ Platform and companion diagnostic technologies from VyGen-Bio will support the development of advanced cell therapies targeting CD38+ cancers, including multiple myeloma. Coeptis will initiate due diligence on VyGen-Bio’s assets, focusing on GEAR-NK cell therapy. The companies aim to leverage their collaboration to improve patient outcomes and expand treatment options in immuno-oncology. Successful completion of this transaction could mark a significant growth milestone for Coeptis.